HeartBeam Shares Are Trading Higher After the FDA Granted the Company 510(k) Clearance of Its System for Comprehensive Arrhythmia Assessment.
HeartBeam Shares Are Trading Higher After the FDA Granted the Company 510(k) Clearance of Its System for Comprehensive Arrhythmia Assessment.
HeartBeam股票在FDA授予公司其綜合性心律失常評估系統的510(k)許可後交易價格上漲。
HeartBeam Shares Are Trading Higher After the FDA Granted the Company 510(k) Clearance of Its System for Comprehensive Arrhythmia Assessment.
HeartBeam股票在FDA授予公司其綜合性心律失常評估系統的510(k)許可後交易價格上漲。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間